Approach to antiarrhythmic therapy in patients with ICDs and frequent activations
- 25 Downloads
Patients with an implantable defibrillator may require concomitant antiarrhythmic drug therapy to reduce therapy from the device, especially shocks from the device. New evidence suggests that amiodarone, in combination with β-blockade, is the most effective treatment to reduce the frequency of defibrillator therapies, but sotalol and azimilide have also been shown to be effective. Electrical storm is a serious condition that occurs in 20% of patients living with a defibrillator, and its management requires a complex approach to the patient.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Bardy GH, Lee KL, Mark DB, et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225–237. The SCD-HeFT trial showed a mortality benefit from ICD therapy but not from amiodarone therapy in patients with heart failure and low ejection fraction.PubMedCrossRefGoogle Scholar
- 4.Moss AJ, Zareba W, Hall WJ, et al.: Prophylactic implantation of a deflbrillator in patients with myocardial infarction and reduced ejection fraction. For the multicenter automatic deflbrillator implantation trial II investigators. N Engl J Med 2002, 346:877–883. The MADIT II study showed a mortality benefit from ICD therapy on top of optimal medical management in patients with ischemic cardiomyopathy and low ejection fraction.PubMedCrossRefGoogle Scholar
- 8.Freedberg NA, Hill JN, Fogel RI, Prystowsky EN: Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy. J Am Coll Cardiol 2001, 37:1910–1915. Recurrence of ventricular arrhythmia requiring treatment from the ICD is frequent following the first ICD therapy. Secondary prophylactic antiarrhythmic drug treatment should be considered.PubMedCrossRefGoogle Scholar
- 14.Whang W, Mittleman MA, Rich DQ, et al.: Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmia (TOVA) study. Circulation 2004, 109:1386–1391. Heart failure is implied as an independent risk factor for recurrent ICD discharge.PubMedCrossRefGoogle Scholar
- 20.Kettering K, Mewis C, Dornberger V, et al.: Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable defibrillator. PACE 2002, 11:1571–1576.Google Scholar
- 24.Dorian P, Borggrefe M, Al-Khalidi HR, et al.: Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004, 110:3646–3654. This randomized trial showed, that azimilide, compared to placebo, reduced the burden of symptomatic ventricular tachyarrhythmia in ICD patients.PubMedCrossRefGoogle Scholar
- 27.Connolly SJ, Hohnloser S, Dorian P, et al.: Optimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients (OPTIC) trial. Presented at the American College of Cardiology Annual Scientific Sessions. Late Breaking Clinical Trials I. Orlando, FL; March 6–9, 2005.Google Scholar
- 31.Boriani G, Lubinski A, Capucci A et al.: A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischemic heart disease. Eur Heart J 2001, 22:2180–2191.PubMedCrossRefGoogle Scholar
- 32.O’Toole M, O’Neill G, Kluger J, et al.: Efficacy and safety of oral dofetilide in patients with an implantable defibrillator: A multicenter study [abstract]. Circulation 1999, 100:1–794.Google Scholar